AgomAb Therapeutics NV (AGMB)
NASDAQ: AGMB · Real-Time Price · USD
10.64
-0.68 (-6.01%)
At close: Apr 28, 2026, 4:00 PM EDT
10.11
-0.53 (-4.98%)
After-hours: Apr 28, 2026, 4:20 PM EDT
AgomAb Therapeutics NV Employees
AgomAb Therapeutics NV had 58 employees as of December 31, 2024. The number of employees increased by 24 or 70.00% compared to the previous year.
Employees
58
Change (1Y)
24
Growth (1Y)
70.00%
Revenue / Employee
n/a
Profits / Employee
-$1,270,551
Market Cap
519.05M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 58 | 24 | 70.00% |
| Dec 31, 2023 | 34 | 33 | 3,300.00% |
| Dec 31, 2019 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ProKidney | 231 |
| CorMedix | 191 |
| Rigel Pharmaceuticals | 174 |
| Sutro Biopharma | 137 |
| Kyverna Therapeutics | 130 |
| Ocugen | 116 |
| Adlai Nortye | 109 |
| Prothena Corporation | 67 |
AGMB News
- 4 days ago - Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook - GlobeNewsWire
- 4 weeks ago - Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 2 months ago - Agomab Announces Closing of Initial Public Offering - GlobeNewsWire
- 2 months ago - Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut - Reuters
- 2 months ago - Agomab Announces Pricing of Initial Public Offering - GlobeNewsWire
- 3 months ago - Agomab Therapeutics files for US IPO - Reuters
- 3 months ago - AgomAb Therapeutics IPO Registration Document (F-1) - SEC